US Fortune 500 companies, international and German start-ups, companies, research institutions and universities rely on Uexküll & Stolberg's expertise in patent dispute resolution. Clients are represented before domestic and European offices and courts, such as the DPMA and EPO, and frequently in opposition proceedings. Practice areas are divided according to discipline: Peter Franck signs responsible for chemistry, Bernd Janssen for technology and Albrecht von Menges heads the biotechnology group.
Legal 500 Editorial commentary
Key clients
- Amgen Inc.
- ExxonMobil
- Monsanto/Bayer
- Janssen Pharmaceutical
- Johnson&Johnson
- Ivoclar
- Bristol-Myers-Squibb / Pfizer
- KRKA
- Medac
- Sealed Air
- W.R. Grace
- Big Ben
- Chinese University of Hong Kong
- Chr. Hansen A/S
- Boehringer Ingelheim
- Ohly GmbH
Work highlights
- Representation of the Bristol Myers-Squibb/Pfizer alliance in several opposition proceedings before the European Patent Office (EPO) against up to eleven opponents.
- Representing Amgen as patent holder in four opposition proceedings before the EPO and in preliminary injunction proceedings in Düsseldorf and Munich against a number of generic drug manufacturers.
- Representation of Ohly GmbH in opposition proceedings before the EPO against patent EP 3 222 156 of Japanese company TableMark Co., Ltd.
Practice head
The lawyer(s) leading their teams.
Peter Franck, Bernd Janssen, Albrecht von Menges